Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma
*To evaluate best objective response rate (ORR)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Minjuvi | Drug | Observation study, collect data only |
| Measure | Description | Time Frame |
|---|---|---|
| objective response rate (ORR) | the proportion of patients achieving a complete or partial response to tafasitamab, based on the Lugano 2014 criteria. | The time from day 1 of tafasitamab treatment initiation to documented disease progression or death |
| Measure | Description | Time Frame |
|---|---|---|
| PFS (Progression-Free Survival) | defined as the time from day 1 of tafasitamab treatment initiation to documented disease progression or death from any cause. | |
| OS (Overall Survival) | the time from day 1 of tafasitamab treatment initiation to death from any cause. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Patients who are alive but unable or unwilling to provide written informed consent.
-
Not provided
Not provided
Not provided
R/R DLBCL who are ineligible for ASCT
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tty Biopharm | Taipei | Taiwan |
Not provided
Not provided
Not provided
Not provided
| DoR (Duration of Response) | the time from day 1 of first documented response (complete or partial) to disease progression or death. |
| TTP (Time to Progression) | the time from day 1 of tafasitamab treatment initiation to tumor progression, with deaths censored if occurring prior to progression |
| TTNT (Time to Next Treatment) | the time from day 1 of tafasitamab treatment initiation to the start of the next anti-neoplastic therapy, regardless of the reason (e.g., disease progression, toxicity, or patient preference) or death from any cause. |
| EFS (Event-Free Survival) | the time from day 1 of tafasitamab treatment initiation to the earliest occurrence of tumor progression, initiation of a new non-study anti-neoplastic therapy, or death from any cause. |